Funding antifungals

Why F2G is sticking with private markets to fund its novel antifungal

On the back of encouraging clinical data for a novel antifungal, a syndicate supplied F2G Ltd. with one of the largest U.K. venture rounds this year.

New investor Sectoral Asset Management led

Read the full 323 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE